Reviews/Motor Neurone Disease Treatment/Riluzole prolongs survival
DMT · MND-DMT-01 · v2
Borderline: within 4 points of the Established/Likely boundary, so a re-grade could land either side.
Two placebo-controlled trials of riluzole in people with motor neurone disease (called ALS in the papers) both found that more patients on the drug were alive after treatment than those on placebo [1][2]. A later re-examination of the larger trial confirmed the survival benefit and located it mainly in the most advanced stage of disease [3], and a separate real-world registry of newly diagnosed patients pointed the same way [4]. The size of the benefit is small throughout, which matches the claim's word 'modestly'. The panel treated the signal as consistent but noted the evidence is less independent than four papers suggest, because two of the trials came from the same research group and the third reuses one trial's data. It also noted that the larger trial's main result only became clearly significant after statistical adjustment, and the registry signal was weak and faded over time.
The 1994 trial found 12-month survival of 74 percent on riluzole versus 58 percent on placebo (P = 0.014) in 155 patients [1]. The larger 1996 dose-ranging trial of 959 patients found 56.8 percent versus 50.4 percent alive without tracheostomy on 100 mg, with an adjusted risk of 0.65 (p = 0.002) and a significant inverse dose response [2]. A retrospective staging analysis of that same trial reported a 35 percent reduction in mortality and concentrated the benefit in the last clinical stage (HR 0.55, 95% CI 0.36-0.83) [3]. An independent population-based registry of 126 incident cases found median survival of 18.2 versus 12.4 months (P = 0.09 overall), significant in bulbar-onset and elderly subgroups [4]. The contested point: The division is over how much independent confirmation the corpus really holds and how robust the headline survival result is. [1] and [2] share investigators and [3] reanalyses [2]'s own dataset, so the four papers reduce to roughly two primary datasets; meanwhile [2]'s registered comparison was non-significant unadjusted (p=0.076) and the only observational evidence [4] was borderline (P=0.09) and transient.
All 6 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Motor Neurone Disease Treatment, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
Evidential independence is overstated by paper count: [1] and [2] share the same investigator group (Bensimon, Lacomblez, Meininger) and [3] is a retrospective reanalysis of [2]'s own dataset, so the corpus holds effectively two primary datasets, not four.
In the pivotal trial [2], the registered 100 mg vs placebo survival comparison was non-significant unadjusted (p=0.076); significance (p=0.002) depended on Cox adjustment for prognostic factors.
Where it remains uncertain. The apparent breadth is narrower than it looks: [1][2] share investigators and [3] reuses [2]'s data, [2]'s result needed Cox adjustment to reach significance, and the independent signal in [4] was only borderline (P=0.09).
Aleatory
Survival percentages in [1] rest on 155 patients and subgroup figures on as few as 15-17 per arm, so point estimates carry substantial random variation.
Epistemic
[1] and [2] share the Bensimon/Lacomblez/Meininger group and [3] reanalyses [2]'s dataset, so the corpus holds effectively two primary datasets rather than four independent confirmations.
Inferential
In [2] the registered endpoint was non-significant unadjusted (p=0.076) and became significant only after Cox adjustment (p=0.002), making the conclusion dependent on the analytic model.
The load-bearing papers from a corpus of 6, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
First RCT showing a significant 12-month survival advantage for riluzole over placebo.
“After 12 months, 45 of 78 patients (58 percent) in the placebo group were still alive, as compared with 57 of 77 patients (74 percent) in the riluzole group (P = 0.014).”
Panel auditInternal validity: high · scope of inference: Outpatients with ALS; the survival advantage was concentrated in bulbar-onset disease, limb-onset not significant (P=0.17).Key limitations: small sample (155) · advantage shrank over longer follow-up · more withdrawals on riluzole (27 vs 17)
Large confirmatory dose-ranging RCT; 100 mg adjusted risk 0.65 (p=0.002) for tracheostomy-free survival.
“This study confirms that riluzole is well tolerated and lengthens survival of patients with ALS.”
Panel auditInternal validity: high · scope of inference: Patients with clinically probable or definite ALS of less than 5 years' duration.Key limitations: unadjusted 100 mg comparison only borderline (0.79, p=0.076) · no functional scale discriminated groups · adverse events dose-dependent
Quantifies the trial survival effect and localises the benefit to late-stage disease.
“Riluzole is the only drug to prolong survival for amyotrophic lateral sclerosis (ALS) and, at a dose of 100 mg, was associated with a 35% reduction in mortality in a clinical trial.”
Panel auditInternal validity: medium · scope of inference: ALS patients at King's stage 4 specifically; transitions from stages 2 or 3 did not differ (p=0.83, p=0.88).Key limitations: retrospective staging · benefit confined to stage 4 · stage 1 effect not analysed
3 of 6 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
Consistent positive RCT and observational evidence on the exact claim, with the modest-effect wording well-calibrated, places this in the Established tier while trial-overlap and adjustment dependence keep it off the ceiling.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
Independent randomised replication. The corpus's two trials share an investigator group and [3] reanalyses [2], so no truly independent RCT confirms the effect. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A placebo-controlled survival trial run by a separate consortium, pre-registering the unadjusted survival comparison as primary.
Open question: Does riluzole's survival benefit replicate in a randomised trial run independently of the original investigator group? Why it is still open: [1] and [2] share investigators and [3] reanalyses [2]'s data, so no independent RCT exists in the corpus.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19